Business Wire

eLichens Raises EUR 7 Million to Boost its Growth in France and Internationally

Jaa

Designer of patented gas sensors and the first comprehensive air quality analysis and prediction platform, eLichens today announced a new EUR 7 million capital increase with its historical investors and two new entrants. This operation, which follows the success of the first raising of capital of over 4 million euros in July 2016, aims to market large volumes of its micro gas sensors to serve the needs of its industrial customers as well as the large-scale deployment of its platform that performs intelligent indoor and outdoor air quality analysis for the smart city, smart home and smart building markets.

The eLichens team relies on patented technologies developed jointly with renowned laboratories such as CEA-Leti and MIT.

In addition to the renewed and strengthened support from current shareholders, including DEMETER, SOFIMAC Innovation, Business Angels networks (members of France Angels) and Aereco, eLichens is delighted to welcome the Fonds Ville de Demain managed by Bpifrance as part of the Future Investment Program and BNP Paribas Développement.

The success of the fundraising reflects the interest and confidence of investors in the company, reinforced by the recent signing of production contracts with major international industrial groups. They wish to capitalize on eLichens' solutions to develop products in the field of worker safety as well as the implementation of urban scenarios to improve air quality in the city of tomorrow. With its unique and proprietary technology platform of indoor/outdoor stations incorporating artificial intelligence, eLichens addresses the markets for urban gas leak detection and analysis and residential and building energy efficiency.

"I am both delighted and proud of the significant progress made within eLichens, which is reflected in the growing attractiveness of our complete range of products, from patented gas sensors to integrated systems, to major industrial groups. The new fundraising initiative demonstrates the confidence shown in the strong potential of our company by historical shareholders and new entrants", says Wahid Issa, CEO of eLichens.

"Since 2016, the eLichens team has demonstrated its strong ability to develop highly innovative air quality analysis and prediction products and solutions. The contracts signed with major customers, in France and internationally, in a wide variety of business sectors confirm the relevance of the solution developed by the company. We are therefore delighted to continue supporting eLichens in this new phase of growth", explains Olivier Bordelanne, Investment Director at DEMETER.

"We are pleased to reiterate our confidence and strengthen our investment in eLichens. The founders brought together some world-renowned advisors and a very talented team. They have kept their promises and eLichens is well equipped to push the benefits of their disruptive sensor technologies and software solutions into the markets for air quality analysis and gas detection. By contributing to more than a third in this new round of funding, Sofimac Innovation is showing its resolve to significantly support companies that started 12 to 18 months earlier, so as to facilitate their international development ambitions", says Nicolas Boulay, Associate Director at SOFIMAC Innovation.

"Air quality, inside and outside our living spaces, is a major health issue. eLichens has developed unique sensor technologies and software to address the air quality market and make their deployment possible. The company has a strong team that has demonstrated its ability to convince several global players of the value of its products. The Fonds Ville de Demain is very happy to support eLichens in its development ambitions", states Laure Michel, Investment Director at Bpifrance.

"Business Angels, members of the France Angels network, have accompanied eLichens since its creation and have mobilized to support its development. This new phase, which Business Angels are supporting, aims to give concrete expression to the worldwide success of an innovative technology with an experienced team in a rapidly developing and vital market, namely that of air quality," says Pascal Péru, Business Angels representative for the eLichens project.

***

About eLichens ( www.elichens.com )

Created in December 2014, eLichens is a start-up with a mission to help individuals digitize their environment. The company relies on a portfolio of patents, know-how and skills, which enable it to develop and market complete sensor/data/services solutions to address the industrial, smart city and consumer markets. eLichens has its headquarters in Grenoble and offices in California.

About Demeter ( www.demeter-im.com ) :

Demeter is a major European private equity player in the field of energy and ecological transition. Its funds invest amounts from EUR 500,000 to EUR 30 million to support companies in the sector at all stages of their development: innovative start-ups, SMEs, fast-growing ETIs and infrastructure projects. Demeter's team comprises 33 staff based in Paris, Grenoble, Metz, Madrid. The company manages EUR 1,000 million and has made 120 investments over the past 12 years.

The EMERTEC 5 fund, an investor in eLichens, is dedicated to providing seed financing to innovative technology companies. The fund, endowed with a little more than EUR 50 million, was raised with the support of the Fonds National d’Amorçage (FNA). The latter is managed by Bpifrance Investissement within the framework of the Future Investment Program and the European Investment Fund (EIF) through the European Union Framework Program for Competitiveness and Innovation (CIP).

About Sofimac Innovation ( www.sofimacpartners.fr/innovation/)

Sofimac Innovation is an independent management company certified by the financial markets regulator (AMF) and dedicated to technological and innovative investment. We are present in Paris, Lyon, Rennes and Aix-en-Provence, as close as possible to the major innovation centers in France. We support innovative start-ups in their growth projects with a wide range of investment vehicles. Working in a wide variety of technological sectors, particularly in the health and digital sectors, our team comprises 10 experienced investor-entrepreneurs specialized in their field. The funds managed by Sofimac Innovation are subscribed by some of the most prestigious public and private institutional investors. Sofimac Innovation currently manages eight funds comprising around 80 active companies.

Sofimac Innovation, together with Sofimac Régions, forms part of the Sofimac Investment Managers group, which has been investing in innovation and growth capital for nearly 40 years. Sofimac IM teams are spread over eight national and regional locations.

About the Future Investment Program

With a budget of EUR 57 billion, the Future Investment Program (Programme d'Investissements d'Avenir – PIA), led by the General Secretariat for Investment, was set up by the French state to finance innovative and promising investments in the country. Six national priorities have thus been identified to enable France to increase its growth and employment potential:

  • higher education, research and training,
  • the commercialization of research and its transfer to the economic world,
  • sustainable development,
  • industry and SMEs,
  • the digital economy,
  • health and biotechnology.

Find out more about future investments: http://www.gouvernement.fr/secretariat-general-pour-l-investissement-sgpi – Twitter : @SGPI_avenir

Endowed with EUR 50 million, the VDD fund, managed by Bpifrance within the framework of the Future Investment Program, provides seed and venture capital to companies that develop technologies and services in the field of the smart city. The VDD fund may invest in start-up companies. The investments are made at the time of the first capital openings and can reach EUR 2 million. The companies targeted develop technological or commercial innovations or provide innovative services.

About Bpifrance

Bpifrance Investissement invests its equity capital through Bpifrance Investissement. Bpifrance finances companies – at every stage of their development – with loans, guarantees and equity. Bpifrance supports them in their innovation projects and internationally. Bpifrance also ensures their export activity through a wide range of products. Consulting, university, networking and acceleration programs for startups, SMEs and ETIs are also part of the offer for entrepreneurs.

Thanks to Bpifrance and its 48 regional offices, entrepreneurs enjoy the services of a close-by, single and efficient point of contact to help them face their challenges.

More information at: www.bpifrance.frwww.presse.bpifrance.fr – Follow us on Twitter: @Bpifrance - @BpifrancePresse

About BNP Paribas Développement

BNP Paribas Développement, a subsidiary of the BNP Paribas Group, is a public limited company created in 1988 and which invests its own funds directly to support the development of high-performing SMEs and ETIs and to ensure their sustainability by facilitating their transfer as minority shareholders. In addition to the financial resources made available to the company to ensure stable resources, the mission of BNP Paribas Développement is to support the management team in carrying out its medium-term strategic project. Our minority position ensures our partners appropriate governance without interference in day-to-day management, while benefiting from the strength of a recognized group and the experience of a partner with a portfolio of over 300 investments. The investment from our own funds guarantees our partners the option of long-term support, adapted to the project and enabling intermediate operations to be carried out: reorganization of capital, external growth, etc. In 2016, BNP Paribas Développement created a structure dedicated to innovation capital which invests in seed capital and in subsequent rounds to support the growth of start-ups with potential.

Find out more at www.bnpparibasdeveloppement.com/

About the Business Angels networks

The Business Angels networks, members of France Angels, are made up of natural persons. The Business Angel invests part of its assets in innovative companies, which also makes its skills, experience, relational networks and part of its time freely available to the company. The Business Angels networks that have participated in supporting eLichens are:

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact information

eLichens
Wahid Issa, +33 (0)6 47 71 01 30
CEO
wahid.issa@elichens.com
or
Demeter
Olivier Bordelanne, +33 (0)6 84 31 71 68
Investment Director
olivier.bordelanne@demeter-im.com
or
Press contact
media@demeter-im.com
or
Sofimac Innovation
Nicolas Boulay, +33 (0)1 45 01 46 46
Associate Director
nicolas.boulay@sofimac-im.com
or
Press contact
Ulysse Communication
Bruno Arabian, +33 (0)6 87 88 47 26
barabian@ulysse-communication.com
or
Press contacts:
Bpifrance
Nicolas Jehly, +33 (0)1 41 79 95 12
nicolas.jehly@bpifrance.fr
or
SGPI
Vincent Deshayes, +33 (0)6 98 60 55 61
vincent.deshayes@pm.gouv.fr
or
BNP Paribas Développement
Anne Toupé, +33 (0)1 40 14 22 70
Director of Investments
anne.toupe@bnpparibas.com
or
Press contact
Olivier Durbize, +33 (0)1 40 14 66 28
olivier.durbize@bnpparibas.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme